08/08/22 4:01 PMNasdaq : CARA earningsCara Therapeutics Reports Second Quarter 2022 Financial Results– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA ™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia ® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validatingRHEA-AIpositive
08/03/22 7:00 AMNasdaq : CARA conferencesCara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth ConferenceCara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief ExecutiveRHEA-AIneutral
08/01/22 4:01 PMNasdaq : CARA earningsCara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audioRHEA-AIneutral
06/30/22 7:00 AMNasdaq : CARA clinical trialCara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieved on the WI-NRS ≥ 4-point responder analysis at Week 8 (p=0.007) – – OralRHEA-AIneutral
05/17/22 7:00 AMNasdaq : CARA conferencesCara Therapeutics to Present at Upcoming Investor ConferencesCara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and ChiefRHEA-AIneutral
05/09/22 4:01 PMNasdaq : CARA earningsCara Therapeutics Reports First Quarter 2022 Financial ResultsKORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients, triggeringRHEA-AIvery positive
05/03/22 4:01 PMNasdaq : CARA conferencesCara Therapeutics to Present at May Investor ConferencesCara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and ChiefRHEA-AIneutral
04/29/22 7:00 AMNasdaq : CARA earningsCara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call andRHEA-AIneutral
04/28/22 1:00 AMNasdaq, OTC : CARA, GNHAY Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patientsFirst approved therapy in Europe for the treatment of chronic kidney disease- associated pruritus in hemodialysis patients First launches in Europe expected in H2 2022. Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. today announced that the European Commission has granted marketing authorization to Kapruvia ® for the treatment...RHEA-AIpositive
04/28/22 1:00 AMNasdaq : CARA Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patientsVifor Fresenius Medical Care Renal PharmaRHEA-AIpositive